Mandate

Vinge is advising Acrinova in its rights issue

Vinge is advising Acrinova AB (publ) in connection with a rights issue which will provide Acrinova with issue proceeds amounting to a maximum of SEK 130 million.

Acrinova is an entrepreneurial-run real estate company operating in southern Sweden with a focus on the Öresund region. Acrinova’s property portfolio is developed through acquisitions, project development and refinement.

Acrinova is listed on Nasdaq First North Growth Market.

Vinge’s team consisted of Linnéa Sellström, Julia Hirschberg and Lorin Arabi.

Related

Vinge has advised Vimian Group AB in connection with its uplisting to Nasdaq Stockholm

Vinge has advised Vimian Group AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm’s main market, Large cap. The prospectus was published on 21 March 2025 and the trading on Nasdaq Stockholm commenced on 28 March 2025.
March 28, 2025

Vinge advises Tribune Therapeutics in conjunction with financing round

Vinge advises Tribune Therapeutics, a Swedish biotechnology company focused on developing therapies for fibrotic diseases, in raising 23 MEUR. The financing round includes the previous investors HealthCap, Novo Holding and Innovestor, in addition to the new investors LifeArc Ventures, Industrifonden and Investinor.
March 26, 2025

Vinge advises Dignitana on the public offer from Paxman

Paxman AB (publ) has announced a public offer to the shareholders of Dignitana AB. The total value of the offer is approximately SEK 153 million.
March 24, 2025